Publications by authors named "C Regnier"
Article Synopsis
- ANV419 Development
- : ANV419 is a novel fusion protein that combines IL-2 with an antibody to specifically activate certain immune cells while minimizing side effects commonly seen with traditional IL-2, like aldesleukin.
- Selective Immune Response
- : The fusion protein preferentially boosts the population of CD8 T cells and natural killer (NK) cells, demonstrating strong anti-tumor effects and improved tolerance levels in clinical testing, especially in mouse models.
- Clinical Potential
- : With a favorable half-life and manageable dosing, ANV419 is being tested in Phase 1/2 clinical trials for treating various cancers, potentially offering patients a safer and more effective alternative to existing IL-
Osteoporosis is a skeletal disease characterized by low bone density and altered microarchitecture, exposing to bone fragility and an increased risk of fracture. Several therapeutic modalities can effectively reduce the risk of fractures both vertebral and non-vertebral. While a significant part of bone strength and structure is genetically determined, it should be recalled that the environment also plays a significant role in these parameters and the risk of fracture, thus offering preventive opportunities thanks to lifestyle.
View Article and Find Full Text PDFBulk analysis of renal allograft biopsies (rBx) identified RNA transcripts associated with acute cellular rejection (ACR); however, these lacked cellular context critical to mechanistic understanding of how rejection occurs despite immunosuppression (IS). We performed combined single-cell RNA transcriptomic and TCR-α/β sequencing on rBx from patients with ACR under differing IS drugs: tacrolimus, iscalimab, and belatacept. We found distinct CD8+ T cell phenotypes (e.
View Article and Find Full Text PDFObjectives: In our study, we explored the specific subgroup of patients with rheumatoid arthritis (RA) suffering from obstructive lung disease (OLD) and its impact on morbi-mortality.
Methods: Our retrospective study included 309 patients suffering from RA with either obstructive (O-RA) or non-obstructive patterns (non-O-RA). OLD was defined based on the Tiffeneau index at the first available pulmonary functional test (PFT).
Bulk analysis of renal allograft biopsies (rBx) identified RNA transcripts associated with acute cellular rejection (ACR); however, these lacked cellular context critical to mechanistic understanding. We performed combined single cell RNA transcriptomic and TCRα/β sequencing on rBx from patients with ACR under differing immunosuppression (IS): tacrolimus, iscalimab, and belatacept. TCR analysis revealed a highly restricted CD8 T cell clonal expansion (CD8 ), independent of HLA mismatch or IS type.
View Article and Find Full Text PDF